Climb Bio, Inc.
CLYMNASDAQHealthcare● Active
$10.77
+$0.22(+2.09%)
Market Cap$734346333
P/E Ratio—
52W High$12.48
52W Low$1.16
Climb Bio, Inc. (CLYM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLYM · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.20
Est. -$0.26 · +23.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CLYM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.23 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.26 | -$0.20 | +23.1% | — | — | — |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.20 | -$0.26 | -30.0% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.16 | -$0.19 | -18.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.19 | -$0.13 | +31.6% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.15 | -$0.31 | -106.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$0.15 | -$0.13 | +13.3% | — | — | — |
| — Q4 FY2024 | Nov 12, 2024 | — | -$0.13 | — | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.26
EPS Surpr.
+23.1%
Revenue
—
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.20
EPS Surpr.
-30.0%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.16
EPS Surpr.
-18.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.19
EPS Surpr.
+31.6%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.15
EPS Surpr.
-106.7%
Revenue
—
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.15
EPS Surpr.
+13.3%
Revenue
—
Q4 FY2024
Nov 12, 2024
EPS Actual
-$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.31 | $-0.31 | $-0.31 | 7 |
| Q3 FY2028 | $-0.30 | $-0.30 | $-0.30 | 4 |
| Q2 FY2028 | $-0.27 | $-0.27 | $-0.27 | 6 |
| Q1 FY2028 | $-0.24 | $-0.24 | $-0.24 | 4 |
| Q4 FY2027 | $-0.28 | $-0.28 | $-0.28 | 6 |
| Q3 FY2027 | $-0.26 | $-0.26 | $-0.26 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +23.1% | $12.22 | $11.91 | -2.54% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -30.0% | $7.28 | $7.39 | +1.51% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -18.8% | $1.92 | $1.95 | +1.56% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +31.6% | $1.65 | $1.61 | -2.42% |
| ▼ Q2 FY2025 | May 14, 2025 | -106.7% | $1.27 | $1.17 | -7.87% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +13.3% | $1.32 | $1.30 | -1.52% |
| — Q4 FY2024 | Nov 12, 2024 | — | $4.06 | $3.80 | -6.40% |
| — Q3 FY2024 | Aug 14, 2024 | — | No price data | $7.83 | — |
Q2 FY2026-2.54%
Report Date
May 7, 2026
EPS Beat/Miss
+23.1%
Price Before
$12.22
Price After
$11.91
Q1 FY2026+1.51%
Report Date
Mar 5, 2026
EPS Beat/Miss
-30.0%
Price Before
$7.28
Price After
$7.39
Q4 FY2025+1.56%
Report Date
Nov 6, 2025
EPS Beat/Miss
-18.8%
Price Before
$1.92
Price After
$1.95
Q3 FY2025-2.42%
Report Date
Aug 12, 2025
EPS Beat/Miss
+31.6%
Price Before
$1.65
Price After
$1.61
Q2 FY2025-7.87%
Report Date
May 14, 2025
EPS Beat/Miss
-106.7%
Price Before
$1.27
Price After
$1.17
Q1 FY2025-1.52%
Report Date
Mar 25, 2025
EPS Beat/Miss
+13.3%
Price Before
$1.32
Price After
$1.30
Q4 FY2024-6.40%
Report Date
Nov 12, 2024
EPS Beat/Miss
—
Price Before
$4.06
Price After
$3.80
Q3 FY2024—
Report Date
Aug 14, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$7.83
Avg Beat Reaction-2.16%
Avg Miss Reaction-1.60%
Beat Rate3 / 8 quarters
Largest Move-7.87% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLYM ends December
Climb Bio, Inc. (CLYM) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.20 — beating the analyst consensus of $-0.26 by +23.1%. The next CLYM earnings date is expected around September 1, 2026.
Each quarter, investors track CLYM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLYM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLYM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLYM earnings · 5 questionsClimb Bio, Inc.'s next earnings report is expected around September 1, 2026. CLYM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLYM historically reports after market close (AMC).
CLYM earnings datewhen is CLYM earningsCLYM next earnings datewhen does CLYM report earningsCLYM earnings calendar
▸ Source: FMP · Climb Bio, Inc. SEC filings · US GAAP · Climb Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026